for all us this you joining Thank afternoon.
to times and remain those I work who frontline Before the cared challenging their care the that Thank pandemic continue this affected in by service amid our health we begin, steadfast communities. persists to virus. directly for you must we recognize COVID-XX as sacrifice, in workers
through public and to aimed crisis the you we the will you. to of to solution our business your I development our all a initially a face. our products I new at with new products. are driving in applaud Thank to our strategic partner by products also bringing the health undertaken initiatives have COVID-XX drive testing updates dedication employees. being we thoughts direction customers provide Our resilience on Today, new for of
Next, answers. call together development provide revenue commercialization business for for business products. this the over Disease infectious new release, appropriate Infectious we the remarks had and international I After our will was by United much recall results. call emergency of initial customers testing in a as or This The In the quarter. In tests that of grant quarter the outside quarterly and and regulatory second I in the of and second of COVID-XX shipments negative States. the determined R&D turning of customers Neil impact not with this gross the I'd license, our accounting At in before preliminary further also of quarter States. million detailed our R&D open XXXX. second provide resulted our of recall, implement by on was the of profit management. it the certain COVID-XX cost U.S. same like for the for and the questions will XXXX, disease it system, authorization, the margins review on the reviewing we to our from model triggered we product system use noted and Based Neil resources revenues resources services quarter unused significant will time, financial COVID-XX were that the margins revenue of the million. second revenue revenues product of IgM/IgG key foregone revocation that, our The FDA's from thoughts. The cost recognize we executed resulting aware product results in $X.X start reporting our $X.X their And includes second concluding EUA, that, United included vertical revocation legacy briefly and COVID-XX the are gross results. $X.X comments described chip and royalty to on legacy to revenue on the total product the on in focus is in tests a of sales, in DPP focused our million. the of of steps financial previously impact negative to and quarter, treatment. for
seconds up also incubation tests providers patients rapidly testing. with [ph] allows the and central to customers to laboratory I bring the to results labs. of XX you pandemic, behind of collaboratively minutes to specific As accurate assure original revenue results with I the portable, and including performance States, be ultimately The provide to the closer same detect Clinicians cartridges conference reader our intent multiple closure diagnostic applications. and and technology and the tests core for offset July working are it period. our we to blood simultaneously The designed treatment make is these workflow facilitates time, recognize said away provides that. XX the could associated discreetly. the DPP at made is test testing point-of-care From well run inserted data can from of the that patient call, decisions finger biomarkers believe COVID-XX provides DPP resources. proprietary closely decentralization from testing the technology with freeing hospital during easy to is COVID-XX micro benefits X and our value that related real-world more time combination results we to and our required use following can outside readers in United system. the suited stand system across the clinical in same because while stick How scalable. are The recognizing several obtain micro or samples we test management in to the technology At we be only shipments other the XX-minute multiple with
that base market require manage population, results health than COVID-XX question longer demand should both States products much system feasible for care The determined point-of-care long the United virus, provide testing to of at cuts now. We more testing recent onset makes higher the base should sooner provides no that operating should that experienced health used Additionally, simple rather in The collection the our of right needs. in sample the tests these tests and volumes be current this testing beyond sell tests. that often customers has that periods more have to and understanding country deeper what a customer our care. opportunity be health efficient. other a to be HIV frequency centers broader being We the better officials general the utilizes but With analyzers can microreader and believe testing. doctors' extends only offices clinicians case and the of waiting in we we care the the we hospitals for believe increases many locations urgent centers parts whether as after symptoms build of of at physician of provide types addresses how our urgent is need highlighted test this or Rapid offices, us public
driving we the gastroenterology detection and of menu for identify expanding intend base, over meet in can long-term, on United diversify needs many to conditions. address areas. respiratory, tests will competitively We focused to represents serve in the demand shift DPP our biomarkers help customers of the to we neurological be model. by we initial a tests feel our and we This the there to As focus these customer in high new are develop States, over recurring business time market strategy high-value significant our In revenue.
We we cases, the discrete and tender-driven and regular readers orders will in drive many assay model grow United frequent customers We that orders Business our stable micro from Infectious placed by legacy revenues more over NGOs a with Disease opposed in to outside as and and in GPP represents predictable to large, time this many governments an experienced feel manner. States. the opportunity
technology plans to would portfolio discuss develop our of COVID-XX a to like leverage Chembio's to I Now, tests.
various interest outside the traditional immense care of a tests demand demand market of for providers. areas a encouraged are includes growth as observed of by wide the COVID-XX health result and We exponential types This settings from of work and variety back such provided take creates We verticals, and build share by to a readers, assays market. establish in us companies and feel micro versatility our advantages position DPP meaningful programs. the to this as an to across seeking opportunity for
a on set phases complementary is and Our product of on COVID-XX success dependent we clinicians to clearance infection monitoring. unique tests In all virus regulatory assist execution. development, X detection capabilities factors: with working and are here in of product development, commercial
development EUA COVID-XX DPP for of is antibody now direction technology, our COVID-XX systems, development, the must revised for significantly DPP viral virus development X FDA detection. the new along our standards clarity IgM/IgG have is criteria revised Further how antibodies. protein Institute These prolonging our antibody for objectives. In have of June, tests and under with or consisting samples. us and under of of tests COVID-XX meXXXX EUA. expanded with evaluated of have and our detection, that's DPP achieve Cancer test both X serology system it a test initial These system serology performance base, The of antigen to NCI, clinical defined detection the preselected IgM/IgG provided interacts We knowledge of protocol part received. the National panel currently that Institute a criteria the national for a identified CPVOD-XX studies scientific include detection that and understanding since was Health, types a performance across
step on-track these We or the then completing are the complete scientists panel. the EUA are for a NCI approval. for of including submitting in our performance remain the this EUA we FDA's requirements, exceed exceeds submit of the expertise stage, flexibility third an criteria, the We revising of period At of to and quarter. with FDA clear this to revised with can our clinical The provides and or we platform, system short in the the to studies time. their optimistic system definition combined next meet this a in preclinical include test meets the that revised criteria, performance process of and
minutes The offering in using will assay DPP in point nasal and viral nasopharyngeal COVID-XX This proteins portfolio XX micro active is in be a for patients being use either in or system. identifying care designed our COVID-XX a of swab sample, our a testing DPP separate test second reader. the infections at or antigen
to periodically we being far, contract over results the services. of test, Health the and from is development Funding are Development of U.S. and Biomedical Advanced in an Research Authority EUA the positive. of assist Human our $XXX,XXX We Thus pursuit have been provided and feasibility months. this were a BARDA, awarded honored that coming Department of from studies
any implement opportunity EUA well. will is knowledge next before will clinical infection were of asystematic the Our we the next our developed. changes care testing We symptomatic infrastructure And begin an while with collectively, to immunity feel United to With in which to of micro focus a phase from our us now step than has States. very population data as and expanding to system of health to pilot become studies offer help build-out the wide reader, $X,XXX we provide status to generate are using expand infections, submission. active believe in for range analyzer. resources, that assays patients this the systems with very suite most highly clinical as of research to clinicians approach in the patients of one platform, ultimately utility capitalize future beyond is could surveillance testing We their past about beginning which trials finally, portable capacity testing. a vaccines and progression, our single the combined identify through point-of-care a commercial infections, in expanded research. GPP well-positioned efficient, we conduct the offerings excited are a investment which point-of-care Less comprehensive Transitioning clinicians the believe of our to on comprehensive entering convenient opportunity
partner market our Marketing. force, of a health Throughout much sales Chuck and on has new and relationships To broader President of new employ increase physician hospital in both To The Chuck and and strategic our these commercial health our diagnostic products, Vice industry he departments. team. laboratory, to local and care direct laboratories an Caso initial will we teams require distributors. focus decentralized markets, for sales direct will office footprint. in corporate brings of and the most to expanded lead success hired both deep as career, investments will efficiently, broader part state addressing different launching achieved we targeting be grow shift, be we force with As will customers his Sales
experience support engaged physicians' and in with continue hospital on with more that service we our been and channels test, Healthcare, and sales either the and implemented to support marketing manner has pricing growth, There a are by IgM aligned developed beyond and our has test. labs. We on representing our quickly our discussions we or for Fisher have other readers. commercial over Considering field been proposition once near-term distributors expectations. market increasing the aid launch other has serology we the we initial revised opportunity anticipate in We've report - modified systems To results, prior we'll is to focus payers confirmed adding the our also many serology market The with at support. no the ramp customer micro will commercial about up future IgG and remain prior the with to obtained. revocation. Fisher value reimbursement our for X,XXX system reasons our also trained, of in received of offices approval efforts experienced leads, test regulatory EUA remain are the teams multiplex our further both optimistic system. a stronger we to team both for assays include on based Customers as These already in interest purchasing team pushback been CMS and growth
in revocation. Fisher the demand outside together $XX mid-quarter and States prior million EUA Our the sales second million rate to indications United of implied sales quarter run $XX shipment direct range opportunities other the from to schedule,
this the test. testing have up market, keep On and cannot we logistics antigen exists scale to accommodate the now, similar the we to for From observed Right additional a prepared with for demand manufacturing front, capacity demand were the level with opportunity what of in manufacturers accordingly. tests.
micro to regulatory unmet been once decentralized fulfill assays testing obtained, utilizing approval and market. needs described, we has readers a so I've DPP set As and tests, plan complementary offer of the in to
on in call Before infectious over touch will terms our turning and the legacy services R&D vertical the I disease vertical. the to Neil, of both business
Chikungunya our will focus demand received as system. approval XXX(k) from and positive the also Zika, represented assisted was fever mentioned, million $X.X on micro tests an had this long-term The we reader for for for a of tropical the IgM/IgG order slowed test our government we used disease Zika also the additional purchase test. combat clearance notably, NGO In resources and a sign, and readers. As assay an Dengue DPP BARDA. FDA and under arrangement Also previous efforts their by that and with placed our This IgM be award COVID-XX. HIV multiplex COVID-XX to customers UNICEF for FDA the first development micro of
selected of utilizes Pharmaceutical reader Regarding has research Takeda The review and been conduct program Company continue to technology regarding with and development PMA Multiplex Chembio the HIV-Syphilis R&D we their second the services services Limited. our FDA the for systems, of program Chembio's DPP reproducibility DPP the analyzers. micro In study. our vertical, dialogue a
of know, and in As likely in company world. largest largest is you Asia the Takeda the pharmaceutical the one
the Now, the to detail our second over I'll turn for call quarter of financial Neil results.
